Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/28/2012 | 10:06pm CET

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at [email protected]

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
12/12 WALKER & DUNLOP : America First Investment Advisors Has Increased By $309,984 It..
12/08 ABBOTT LABORATORIES : Q-- Altoona/Butler/Wilmington VAMC Chemistry/Immunoassay A..
12/08 ABBOTT LABORATORIES : $3.82 Million Federal Contract Awarded to Abbott Laborator..
12/07 ABBOTT LABORATORIES : Researchers Submit Patent Application, "Container", for Ap..
12/07 ABBOTT LABORATORIES : ' Trademark Application for "PEDIALYTE SINGLES" Filed
12/06 ABBOTT LABORATORIES : To present at j.p. morgan healthcare conference
12/04 ABBOTT : to Present at J.P. Morgan Healthcare Conference
12/01 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
11/30 ABBOTT LABORATORIES : An Application for the Trademark "UNIVANTS OF HEALTHCARE E..
11/30 ABBOTT LABORATORIES : New Xanthophylls Study Findings Have Been Reported by Rese..
More news
News from SeekingAlpha
03:03a I'm Sticking With CVS And Walgreens, My Last Two Losers
12/12 Premarket analyst action - healthcare
12/10 Dividend Income Update November 2017
12/05 YOUR DAILY PHARMA SCOOP : Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Pos..
12/04 My Dividend Growth Portfolio Update - 48 Holdings, 1 Buy
Financials ($)
Sales 2017 27 185 M
EBIT 2017 6 008 M
Net income 2017 2 227 M
Debt 2017 19 729 M
Yield 2017 1,92%
P/E ratio 2017 47,28
P/E ratio 2018 35,22
EV / Sales 2017 4,29x
EV / Sales 2018 3,78x
Capitalization 96 951 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 62,0 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Randel W. Woodgrift VP-Abbott Medical Devices Cardiovascular
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES42.38%95 629
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659